Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues

The study shows partial antiviral activity of maraviroc (MVC) when tested in multiple preclinical dosing strategies

From:
Department for International Development
Published
1 January 2016
Document Type:
Journal Article
Theme:
Health
Authors:
Shattock, R.J., Fletcher, P., Nuttall, J., Armanasco, N., Herrera, C.

Abstract

The potential of maraviroc (MVC), a small-molecule CCR5 antagonist, as a candidate to prevent HIV-1 sexual transmission by oral or topical dosing has not yet been completely established. Using relevant cellular and mucosal tissue explant models, the authors show partial antiviral activity of MVC when tested in multiple preclinical dosing strategies.

Citation

Fletcher, P.; Herrera, C.; Armanasco, N.; Nuttall, J.; Shattock, R.J. Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues. AIDS Research and Human Retroviruses (2016) 32 (4) 334-338. [DOI: 10.1089/aid.2015.0315]

Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues

Updates to this page

Published 1 January 2016
Contents